Subscribe to Search results

Notes on Transfusion by Ministry of Health warned of risks of transfusion.

Published on:

A parent of a Treloar's student provided consent for their son to take part in a DDAVP trial but asked for further information about this "other substance".

Published on:

In 1976 over 600,000 units of cryoprecipitate, just over 150,000 units of NHS Factor 8 and over 1,000,000 units of three different commercial concentrates were used at Treloar's.

Published on:

In 1977 cryoprecipitate and NHS factor concentrates were both used at Treloar's, as well as four commercial products.

Published on:

Blood Concentrate products were most probably first used at Treloar's after March 1969.

Published on:

In a letter to Dr Maycock, Dr Rainsford stated that the Treloar's students had not been adequately treated with AHG before he had arrived at the school.

Published on:

Dr Iain Frew, the home clinician of a Treloar's student, wrote to Dr Aronstam regarding the higher doses of cryoprecipitate provided by Treloar's.

Published on:

Dr Aronstam stated in a letter that the use of prophylaxis was a routine at Treloar's "in many clinical situations" and described the programme as "admittedly enthusiastic".

Published on:

Stephen Nicholls recollected that prophylaxis treatment was really pushed at Treloar's.

Published on:

Following two trials, Dr Aronstam recognised the potential where prophylaxis reduced the frequency of bleeding episodes and the potential danger of hyper-transfusion with blood products.

Published on:

Dr Swinburne (Leeds Haemophilia Centre) suggested that it was wise that the patient be treated with one product and Hemofil was recommended.

Published on:

Dr Aronstam stated that Treloar's patients had already had five different types of concentrates and he prefered not to "confine [himself] to a single Concentrate."

Published on:

Dr Rizza suggested that some of the Treloar's pupils, if possible, should receive NHS material.

Published on:

Dr Aronstam wrote that prophylaxis was "much more effective given on alternate days than twice weekly".

Published on:

Dr Aronstam stated that he had not seen hard data to prove the benefits of lower doses of Factor 8.

Published on:

Dr Aronstam stated "we only give prophylaxis in short courses here and only when a particular joint is being threatened. I am afraid we do not have the resources to give any of our 55 severe haemophiliac boys a long course of prophylaxis just because of bleeding frequency".

Published on:

The chief executive of Speywood stated that Dr Aronstam's "first requirement is convenience of administration" when deciding what treatment to provide to Treloar's students.

Published on:

Dr Kirk provided information in 1976 to the Bournemouth Department of Pathology about a pupil who was negative for HbsAg and HBsAb and had a presumptive diagnosis of non-B hepatitis "probably associated with the transfusion of Kryobulin".

Published on:

Dr Painter spoke to some parents in early 1978, and appeared to regard Hepatitis B which had become chronic as potentially leading to a grim future, and a matter of significant concern.

Published on:

Dr Craske highlighted to Dr Aromstam that mixing the blood products of different manufacturers might increase the risks of hepatitis and advised that it might be wise to confine students to one type of material.

Published on: